{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:57:10Z","timestamp":1791237430173,"version":"4.1.0"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.msard.2024.105681","type":"journal-article","created":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T15:53:08Z","timestamp":1715442788000},"page":"105681","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Neurological efficacy and safety of mesenchymal stem cells (MSCs) therapy in people with multiple sclerosis (pwMS): An updated systematic review and meta-analysis"],"prefix":"10.1016","volume":"87","author":[{"given":"Saeed","family":"Vaheb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahra","family":"Afshin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed","family":"Ghoshouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham Moases","family":"Ghaffary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahour","family":"Farzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahid","family":"Shaygannejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangharsha","family":"Thapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aram","family":"Zabeti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Mirmosayyeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.msard.2024.105681_bib0065","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/nn.3109","article-title":"Hepatocyte growth factor mediates mesenchymal stem cell\u2013induced recovery in multiple sclerosis models","volume":"15","author":"Bai","year":"2012","journal-title":"Nat. Neurosci."},{"issue":"4","key":"10.1016\/j.msard.2024.105681_bib0030","doi-asserted-by":"crossref","DOI":"10.1177\/2055217319887198","article-title":"Serum neurofilament light chain concentration in a phase 1\/2 trial of autologous mesenchymal stem cell transplantation","volume":"5","author":"Baldassari","year":"2019","journal-title":"Multiple Sclerosis J.\u2013Exp. Transl. Clin."},{"issue":"4","key":"10.1016\/j.msard.2024.105681_bib0031","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.arcmed.2013.03.007","article-title":"Evaluation of cytokines in multiple sclerosis patients treated with mesenchymal stem cells","volume":"44","author":"Bonab","year":"2013","journal-title":"Arch. Med. Res."},{"issue":"5","key":"10.1016\/j.msard.2024.105681_bib0015","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/cbin.11313","article-title":"Mesenchymal stromal cell-derived extracellular vesicles as cell-free biologics for the ex vivo expansion of hematopoietic stem cells","volume":"44","author":"Budgude","year":"2020","journal-title":"Cell Biol. Int."},{"issue":"3","key":"10.1016\/j.msard.2024.105681_bib0008","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S1474-4422(09)70017-1","article-title":"Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I\/II study","volume":"8","author":"Burt","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2024.105681_bib0062","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2017-317509","article-title":"Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis?","author":"Cerqueira","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.msard.2024.105681_bib0044","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/1352458517703802","article-title":"Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis","volume":"24","author":"Cohen","year":"2018","journal-title":"Mult. Sclerosis J."},{"issue":"1","key":"10.1016\/j.msard.2024.105681_bib0023","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1177\/13524585221122156","article-title":"Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosis","volume":"29","author":"Cohen","year":"2023","journal-title":"Multiple Sclerosis J."},{"issue":"2","key":"10.1016\/j.msard.2024.105681_bib0022","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S1474-4422(11)70305-2","article-title":"Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study","volume":"11","author":"Connick","year":"2012","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.msard.2024.105681_bib0005","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3390\/biomedicines7020026","article-title":"Stem cell-based therapies for multiple sclerosis: current perspectives","volume":"7","author":"Cuascut","year":"2019","journal-title":"Biomedicines."},{"issue":"11","key":"10.1016\/j.msard.2024.105681_bib0045","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/cns.12759","article-title":"Mesenchymal stem cells and conditioned media in the treatment of multiple sclerosis patients: clinical, ophthalmological and radiological assessments of safety and efficacy","volume":"23","author":"Dahbour","year":"2017","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.msard.2024.105681_bib0002","first-page":"1","article-title":"Advances in nanotechnology versus stem cell therapy for the theranostics of multiple sclerosis disease","author":"Damavandi","year":"2022","journal-title":"Appl. Nanosci."},{"issue":"1","key":"10.1016\/j.msard.2024.105681_bib0006","first-page":"91","article-title":"Autologous stem cell transplantation aids autoimmune patients by functional renewal and TCR diversification of regulatory T cells. Blood","volume":"127","author":"Delemarre","year":"2016","journal-title":"J. Am. Soc. Hematol."},{"issue":"6","key":"10.1016\/j.msard.2024.105681_bib0066","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1523\/JNEUROSCI.3803-11.2012","article-title":"Exogenous leukemia inhibitory factor stimulates oligodendrocyte progenitor cell proliferation and enhances hippocampal remyelination","volume":"32","author":"Deverman","year":"2012","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.msard.2024.105681_bib0029","doi-asserted-by":"crossref","DOI":"10.1177\/2055217319856035","article-title":"Exploratory MRI measures after intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis","volume":"5","author":"Feng","year":"2019","journal-title":"Multiple Sclerosis Journal\u2013Experimental, Translational and Clinical."},{"issue":"5","key":"10.1016\/j.msard.2024.105681_bib0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195891","article-title":"Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: a triple blinded, placebo controlled, randomized phase I\/II safety and feasibility study","volume":"13","author":"Fern\u00e1ndez","year":"2018","journal-title":"PLoS ONE"},{"issue":"12","key":"10.1016\/j.msard.2024.105681_bib0010","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.it.2004.09.012","article-title":"New directions in MS therapeutics: vehicles of hope","volume":"25","author":"Fox","year":"2004","journal-title":"Trends Immunol."},{"issue":"4","key":"10.1016\/j.msard.2024.105681_bib0011","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1177\/1352458509359727","article-title":"The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group","volume":"16","author":"Freedman","year":"2010","journal-title":"Multiple Sclerosis J."},{"issue":"5","key":"10.1016\/j.msard.2024.105681_bib0004","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/brain\/awp070","article-title":"The relation between inflammation and neurodegeneration in multiple sclerosis brains","volume":"132","author":"Frischer","year":"2009","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.msard.2024.105681_bib0069","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1517\/17425247.2012.668521","article-title":"Delivering bioactive molecules as instructive cues to engineered tissues","volume":"9","author":"Gabriel","year":"2012","journal-title":"Expert Opin. Drug. Deliv."},{"key":"10.1016\/j.msard.2024.105681_bib0003","first-page":"145","article-title":"Stem cell therapy for multiple sclerosis","author":"Genc","year":"2019","journal-title":"Tissue Eng. Regen. Med."},{"key":"10.1016\/j.msard.2024.105681_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13287-018-0951-9","article-title":"Cell therapy induced regeneration of severely atrophied mandibular bone in a clinical trial","volume":"9","author":"Gjerde","year":"2018","journal-title":"Stem Cell Res. Ther"},{"issue":"3","key":"10.1016\/j.msard.2024.105681_bib0027","first-page":"520","article-title":"EndNote 20 desktop version","volume":"109","author":"Gotschall","year":"2021","journal-title":"J. Med. Lib. Assoc.: JMLA"},{"issue":"9","key":"10.1016\/j.msard.2024.105681_bib0007","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/sj.bmt.1704892","article-title":"Autologous hematopoietic stem cell transplantation for autoimmune diseases","volume":"35","author":"Gratwohl","year":"2005","journal-title":"Bone Marrow Transplant."},{"issue":"7","key":"10.1016\/j.msard.2024.105681_bib0064","doi-asserted-by":"crossref","first-page":"536","DOI":"10.5966\/sctm.2012-0015","article-title":"Characterization of autologous mesenchymal stem cell-derived neural progenitors as a feasible source of stem cells for central nervous system applications in multiple sclerosis","volume":"1","author":"Harris","year":"2012","journal-title":"Stem Cells Transl. Med."},{"issue":"12","key":"10.1016\/j.msard.2024.105681_bib0046","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jcyt.2016.08.007","article-title":"Clinical safety of intrathecal administration of mesenchymal stromal cell\u2013derived neural progenitors in multiple sclerosis","volume":"18","author":"Harris","year":"2016","journal-title":"Cytotherapy"},{"key":"10.1016\/j.msard.2024.105681_bib0019","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ebiom.2018.02.002","article-title":"Phase I trial of intrathecal mesenchymal stem cell-derived neural progenitors in progressive multiple sclerosis","volume":"29","author":"Harris","year":"2018","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.msard.2024.105681_bib0039","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000928","article-title":"Mesenchymal stem cell-derived neural progenitors in progressive MS: two-year follow-up of a phase I study","volume":"8","author":"Harris","year":"2021","journal-title":"Neurol.-Neuroimmunol.Neuroinflammat."},{"key":"10.1016\/j.msard.2024.105681_bib0028","first-page":"343","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.msard.2024.105681_bib0067","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.expneurol.2016.02.023","article-title":"The role of growth factors as a therapeutic approach to demyelinating disease","volume":"283","author":"Huang","year":"2016","journal-title":"Exp. Neurol."},{"issue":"12","key":"10.1016\/j.msard.2024.105681_bib0055","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.3390\/jcm8122102","article-title":"Short and long term clinical and immunologic follow up after bone marrow mesenchymal stromal cell therapy in progressive multiple sclerosis\u2014a phase I study","volume":"8","author":"Iacobaeus","year":"2019","journal-title":"J Clin. Med."},{"issue":"19","key":"10.1016\/j.msard.2024.105681_bib0025","doi-asserted-by":"crossref","first-page":"6311","DOI":"10.3390\/jcm12196311","article-title":"Mesenchymal stem cell therapy in multiple sclerosis: a systematic review and meta-analysis","volume":"12","author":"Islam","year":"2023","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.msard.2024.105681_bib0014","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/stem.727","article-title":"Concise review: induced pluripotent stem cell-derived mesenchymal stem cells: progress toward safe clinical products","volume":"30","author":"Jung","year":"2012","journal-title":"Stem Cells"},{"issue":"3","key":"10.1016\/j.msard.2024.105681_bib0057","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.stem.2009.02.001","article-title":"Mesenchymal stem cell homing: the devil is in the details","volume":"4","author":"Karp","year":"2009","journal-title":"Cell Stem Cell"},{"issue":"10","key":"10.1016\/j.msard.2024.105681_bib0052","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1001\/archneurol.2010.248","article-title":"Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis","volume":"67","author":"Karussis","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.msard.2024.105681_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.891514","article-title":"Safety and clinical efficacy of mesenchymal stem cell treatment in traumatic spinal cord injury, multiple sclerosis and ischemic stroke\u2013a systematic review and meta-analysis","volume":"13","author":"Kvistad","year":"2022","journal-title":"Front. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2024.105681_bib0074","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/stem.430","article-title":"A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke","volume":"28","author":"Lee","year":"2010","journal-title":"Stem Cells"},{"issue":"1_suppl","key":"10.1016\/j.msard.2024.105681_bib0036","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3727\/096368914X685005","article-title":"The potential of human umbilical cord-derived mesenchymal stem cells as a novel cellular therapy for multiple sclerosis","volume":"23","author":"Li","year":"2014","journal-title":"Cell Transplant."},{"issue":"12","key":"10.1016\/j.msard.2024.105681_bib0021","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113936","article-title":"Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis","volume":"9","author":"Llufriu","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.msard.2024.105681_bib0040","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3389\/fneur.2020.00967","article-title":"IV\/IT hUC-MSCs infusion in RRMS and NMO: a 10-year follow-up study","volume":"11","author":"Lu","year":"2020","journal-title":"Front. Neurol"},{"issue":"2","key":"10.1016\/j.msard.2024.105681_bib0071","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1474-4422(14)70256-X","article-title":"Pathological mechanisms in progressive multiple sclerosis","volume":"14","author":"Mahad","year":"2015","journal-title":"Lancet Neurol."},{"issue":"7","key":"10.1016\/j.msard.2024.105681_bib0009","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S1474-4422(08)70138-8","article-title":"Autologous haematopoietic stem-cell transplantation in multiple sclerosis","volume":"7","author":"Mancardi","year":"2008","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.msard.2024.105681_bib0013","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nrneurol.2010.35","article-title":"Stem cell transplantation in multiple sclerosis: current status and future prospects","volume":"6","author":"Martino","year":"2010","journal-title":"Nature Rev. Neurol."},{"issue":"1\u20132","key":"10.1016\/j.msard.2024.105681_bib0053","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jns.2008.06.032","article-title":"Compartmentalization of inflammation in the CNS: a major mechanism driving progressive multiple sclerosis","volume":"274","author":"Meinl","year":"2008","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.msard.2024.105681_bib0043","first-page":"212","article-title":"Umbilical cord mesenchymal stem cell transplantation in the treatment of multiple sclerosis","volume":"10","author":"Meng","year":"2018","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.msard.2024.105681_bib0001","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jocn.2023.01.006","article-title":"Prevalence of dysphagia in patients with multiple sclerosis: a systematic review and meta-analysis","volume":"108","author":"Mirmosayyeb","year":"2023","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.msard.2024.105681_bib0051","author":"Mohy","year":"2007","journal-title":"Does Mesenchymal Stem Cell Therapy Help Multiple Sclerosis patients?"},{"issue":"6","key":"10.1016\/j.msard.2024.105681_bib0048","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2174\/157488812804484648","article-title":"Autologous mesenchymal stem cell therapy in progressive multiple sclerosis: an open label study","volume":"7","author":"Mohyeddin Bonab","year":"2012","journal-title":"Curr. Stem Cell Res. Ther."},{"issue":"7","key":"10.1016\/j.msard.2024.105681_bib0056","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1002\/stem.1111","article-title":"Are therapeutic human mesenchymal stromal cells compatible with human blood?","volume":"30","author":"Moll","year":"2012","journal-title":"Stem Cells"},{"key":"10.1016\/j.msard.2024.105681_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104895","article-title":"Intravenous transplantation of bone marrow-derived mesenchymal stromal cells in patients with multiple sclerosis, a phase I\/IIa, double blind, randomized controlled study","volume":"78","author":"Nabavi","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2 Pt 2","key":"10.1016\/j.msard.2024.105681_bib0049","first-page":"72","article-title":"Transplantation of mesenchymal stem cells in multiple sclerosis","volume":"111","author":"Odinak","year":"2011","journal-title":"Zhurnal nevrologii i psikhiatrii imeni SS Korsakova"},{"key":"10.1016\/j.msard.2024.105681_bib0059","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101860","article-title":"Growing evidence supporting the use of mesenchymal stem cell therapies in multiple sclerosis: a systematic review","volume":"38","author":"Oliveira","year":"2020","journal-title":"Mult. Scler. Relat. Disord"},{"key":"10.1016\/j.msard.2024.105681_bib0026","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.msard.2024.105681_bib0020","doi-asserted-by":"crossref","DOI":"10.4067\/S0717-95022022000100143","article-title":"Efficiency and safety of umbilical cord mesenchymal stromal\/stem cells in multiple sclerosis combined treatment","volume":"40","author":"Petriv","year":"2022","journal-title":"Int. J. Morphol."},{"issue":"1","key":"10.1016\/j.msard.2024.105681_bib0060","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4067\/S0717-95022022000100143","article-title":"Eficacia y Seguridad de las C\u00e9lulas Madre\/Estromales Mesenquimales del Cord\u00f3n Umbilical en el Tratamiento Combinado de la Esclerosis M\u00faltiple","volume":"40","author":"Petriv","year":"2022","journal-title":"Int. J. Morphol."},{"issue":"12","key":"10.1016\/j.msard.2024.105681_bib0034","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1093\/brain\/awaa333","article-title":"Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis","volume":"143","author":"Petrou","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.msard.2024.105681_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.639315","article-title":"Long-term clinical and immunological effects of repeated mesenchymal stem cell injections in patients with progressive forms of multiple sclerosis","volume":"12","author":"Petrou","year":"2021","journal-title":"Front. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2024.105681_bib0016","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41536-019-0083-6","article-title":"Mesenchymal stem cell perspective: cell biology to clinical progress","volume":"4","author":"Pittenger","year":"2019","journal-title":"NPJ. Regen. Med."},{"issue":"9","key":"10.1016\/j.msard.2024.105681_bib0070","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/nrd.2017.115","article-title":"Remyelination therapies: a new direction and challenge in multiple sclerosis","volume":"16","author":"Plemel","year":"2017","journal-title":"Nature Rev. Drug Discov."},{"issue":"8","key":"10.1016\/j.msard.2024.105681_bib0073","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1089\/scd.2010.0466","article-title":"Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans","volume":"20","author":"Ra","year":"2011","journal-title":"Stem Cells Dev."},{"issue":"1","key":"10.1016\/j.msard.2024.105681_bib0042","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-018-1433-7","article-title":"Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis","volume":"16","author":"Riordan","year":"2018","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.msard.2024.105681_bib0061","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-018-1433-7","article-title":"Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis","volume":"16","author":"Riordan","year":"2018","journal-title":"J. Transl. Med."},{"issue":"2","key":"10.1016\/j.msard.2024.105681_bib0047","doi-asserted-by":"crossref","first-page":"71","DOI":"10.5812\/archneurosci.13687","article-title":"Intrathecal mesenchymal stem cell therapy in multiple sclerosis: a follow-up study for five years after injection","volume":"1","author":"Sahraian","year":"2014","journal-title":"Arch. Neurosci."},{"issue":"2","key":"10.1016\/j.msard.2024.105681_bib0041","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1080\/08820139.2018.1504301","article-title":"Therapeutic use of intrathecal mesenchymal stem cells in patients with multiple sclerosis: a pilot study with booster injection","volume":"48","author":"Sahraian","year":"2019","journal-title":"Immunol. Invest."},{"issue":"6","key":"10.1016\/j.msard.2024.105681_bib0012","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.3349\/ymj.2012.53.6.1059","article-title":"Neurorestoration induced by mesenchymal stem cells: potential therapeutic mechanisms for clinical trials","volume":"53","author":"Seo","year":"2012","journal-title":"Yonsei Med. J."},{"issue":"5","key":"10.1016\/j.msard.2024.105681_bib0054","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41573-021-00139-y","article-title":"Strategies for delivering therapeutics across the blood\u2013brain barrier","volume":"20","author":"Terstappen","year":"2021","journal-title":"Nature Rev. Drug Discov."},{"key":"10.1016\/j.msard.2024.105681_bib0032","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.clinph.2022.01.125","article-title":"Neurophysiological outcomes following mesenchymal stem cell therapy in multiple sclerosis","volume":"136","author":"Tremblay","year":"2022","journal-title":"Clin. Neurophysiol."},{"issue":"11","key":"10.1016\/j.msard.2024.105681_bib0033","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1474-4422(21)00301-X","article-title":"Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial","volume":"20","author":"Uccelli","year":"2021","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.msard.2024.105681_bib0037","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/09273940601147737","article-title":"Vitreous hemorrhage in multiple sclerosis-associated uveitis","volume":"15","author":"Valentincic","year":"2007","journal-title":"Ocul. Immunol. Inflamm."},{"issue":"5","key":"10.1016\/j.msard.2024.105681_bib0072","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1089\/scd.2007.0201","article-title":"Biodistribution, long-term survival, and safety of human adipose tissue-derived mesenchymal stem cells transplanted in nude mice by high sensitivity non-invasive bioluminescence imaging","volume":"17","author":"Vilalta","year":"2008","journal-title":"Stem Cells Dev."},{"issue":"7","key":"10.1016\/j.msard.2024.105681_bib0058","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/stem.1118","article-title":"Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation","volume":"30","author":"Von Bahr","year":"2012","journal-title":"Stem Cells"},{"issue":"14","key":"10.1016\/j.msard.2024.105681_bib0063","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS","volume":"26","author":"Walton","year":"2020","journal-title":"Mult. Scleros. J."},{"issue":"1\u20132","key":"10.1016\/j.msard.2024.105681_bib0050","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jneuroim.2010.07.013","article-title":"Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study","volume":"227","author":"Yamout","year":"2010","journal-title":"J. Neuroimmunol."},{"issue":"11","key":"10.1016\/j.msard.2024.105681_bib0068","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/glia.20840","article-title":"GDNF-enhanced axonal regeneration and myelination following spinal cord injury is mediated by primary effects on neurons","volume":"57","author":"Zhang","year":"2009","journal-title":"Glia"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482400258X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482400258X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T12:07:51Z","timestamp":1720872471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482400258X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":74,"alternative-id":["S221103482400258X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2024.105681","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurological efficacy and safety of mesenchymal stem cells (MSCs) therapy in people with multiple sclerosis (pwMS): An updated systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2024.105681","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105681"}}